FIGURE 7.

CSTB is significantly upregulated in pancreatic cancer and has clinical significance. (A) Diagram showing the PDX procedure and dosing regime in the therapy model; mice were given intratumoral injections of AAV twice a week for 4 weeks. (B) Representative HE images of primary tumour (F0) and PDX (F3) tumour tissue samples. (C) Gross view of PDX model 4 weeks after AAV injection. Left xenografts were treated with scramble AAV while right xenografts were treated with CSTB‐targeting AAV. (D) Xenografts’ weight was evidently decreased when treated with CSTB‐targeting AAV. (E) Representative IHC images of CSTB expression in Ruijin TMA spotted with human PDAC tissue cores. (F) Respective sample counts in tumour tissues and adjacent tissues. (G) Heatmap shows the counted numbers of four levels of CSTB expression and its correlation with TNM classification. (H) Kaplan–Meier analysis of overall survival rate related to the expression of CSTB expression in Ruijin TMA. (I) CSTB concentration in the serum of 56 healthy donors and 57 PDAC patients. (J) Representative IHC images of CSTB in different stages of PDAC progression in KPC mice. *p < .05, **p < .01, ***p < .001, and ****p < .0001